Together, CARMELINA and CAROLINA constitute
a comprehensive CV outcomes trial programme

CARMELINA and CAROLINA constitute a comprehensive CVOT programme
demonstrating the long-term safety profile of linagliptin in a broad range of patients with T2D

Click on the logos below or use the tabs at the top of the page to learn more about each trial

CV, cardiovascular; CKD, chronic kidney disease; HbA1c, glycated haemoglobin; T2D, type 2 diabetes
1. Rosenstock J et al. JAMA 2019;321:69; 2. Marx N et al. Diab Vasc Dis Res 2015;12:164; 3. Rosenstock J et al. JAMA 2019: doi: 10.1001/jama.2019.13772

For more details

Visit the CAROLINA page for information on the trial design, endpoints, patient population, results and implications

Click here to access the page

Visit the CARMELINA page for information on the trial design, endpoints, patient population, results and implications

Click here to access the page

Visit the resources page for links to publications and other resources for both trials

Click here to access the page

©2019 Boehringer Ingelheim International GmbH. All rights reserved.